Home > Gastroenterology > Pfizer’s bowel disease drug succeeds in late-stage study

Pfizer’s bowel disease drug succeeds in late-stage study


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Reuters - 23/03/2022 - Pfizer Inc said on Wednesday its experimental treatment for an inflammatory bowel disease, acquired last year as part of its $6.7 billion deal for Arena Pharmaceuticals, succeeded in a late-stage trial.  The study was testing the efficacy and safety of etrasimod in patients with moderate to severe ulcerative colitis, a chronic inflammatory disease of the colon that leads to ulcers causing abdominal pain, bloody stools and incontinence.  Inflammatory bowel disease is a $20 billion market globally, making it a lucrative target for drugmakers.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on